

MEETING REPORT

WHO HIVResNet MEETING REPORT

21 OCTOBER 2018, JOHANNESBURG, SOUTH AFRICA



MEETING REPORT

**WHO
HIVResNet
MEETING
REPORT**

21 OCTOBER 2018, JOHANNESBURG, SOUTH AFRICA



**World Health
Organization**

WHO HIVResNet meeting report, Johannesburg, South Africa, 21 October 2018

ISBN 978-92-4-000353-8 (electronic version)

ISBN 978-92-4-000354-5 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO HIVResNet meeting report, Johannesburg, South Africa, 21 October 2018. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgements	iv
Background	v
Executive summary	vi
Session 1: Sanger versus next-generation sequencing: optimal reporting thresholds for comparability and reproducibility	1
Session 2: Could a more affordable genotyping test affect its use in clinical practice in low- and middle-income countries and how?	2
Session 3: What is the risk of HIV drug resistance emerging among pre-exposure prophylaxis (PrEP) users in low- and middle-income countries?	4
Session 4: Dolutegravir roll out in the context of non-nucleoside reverse-transcriptase (NNRTI) pretreatment HIV drug resistance	5
DTG roll-out in PEPFAR-supported countries	5
DTG and country response to pretreatment HIV drug resistance	6
How do pretreatment HIV drug resistance survey data inform national antiretroviral therapy guidelines?	6
Experience from Uganda	6
Session 5: How can HIV drug resistance inform antiretroviral therapy switching strategy options?	8
Programmatic considerations on the implementation of the viral load algorithm: Experience from Uganda	8
Considerations on using a single viral load to trigger switch in people for whom NNRTI-based antiretroviral therapy has failed: a modelling exercise	9
Viral load resuppression among people receiving EFV with and without acquired drug resistance at first elevated viral load	9
Viral load resuppression among people receiving second-line PI-based antiretroviral therapy with and without acquired drug resistance	9
Session 6: How do we interpret integrase genotypes for DTG?	11
Session 7: What are the challenges and knowledge gaps related to the use of integrase strand-transfer inhibitors (INSTIs) in low- and middle-income countries?	12
Session 8: Country experience with DTG, viral failure and drug resistance	13
Experience from Brazil	13
Experience from Kenya	13
Experience from Botswana	14
Session 9: Doravirine and new drugs in the pipeline: HIV drug resistance profile and potential role in HIV treatment in low- and middle-income countries	15
Session 10: How can we monitor progress in addressing the research gaps of the Global Action Plan?	16
Annex 1. Meeting agenda	17
Annex 2. List of participants	19

ACKNOWLEDGEMENTS

The report was written by Neil Parkin, under the coordination of Silvia Bertagnolio (WHO, HIV Department). We are extremely grateful for the inputs received by the HIVResNet meeting participants and to the presenters who have reviewed and approved the content of this report. We acknowledge the contributions of David Breuer for technical editing and L'IV Com Sàrl for layout.

BACKGROUND

The WHO HIV drug resistance network (WHO HIVResNet) is a large body of international experts, researchers, laboratorians, organizations, partners, stakeholders and civil society members with an advisory and implementation role to prevent, monitor and respond to HIV drug resistance. Established in 2004 by a partnership between WHO and the International AIDS Society, WHO HIVResNet supports activities to monitor and control the emergence of HIV drug resistance, optimize the use of HIV drug resistance testing, monitor the quality of antiretroviral therapy delivery for the purpose of preventing HIV drug resistance and support policies related to optimal first- and second-line antiretroviral therapy selection.

HIVResNet and its five working groups support the Global Action Plan on HIV drug resistance (<https://www.who.int/hiv/pub/drugresistance/hivdr-action-plan-2017-2021/en>). The goal of the Global Action Plan is to articulate synergistic actions required to prevent HIV drug resistance from undermining global targets on health and HIV and to provide the most effective treatment to all people living with HIV. The Global Action Plan has five strategic objectives:

1. prevention and response;
2. monitoring and surveillance;
3. research and innovation;
4. laboratory capacity; and
5. governance and enabling mechanisms.

This meeting took place immediately before the 27th International Workshop on HIV Drug Resistance and Treatment Strategies in Johannesburg, South Africa, capitalizing on the presence of HIVResNet members, key opinion leaders and other WHO advisers. Annexes 1 and 2 present the meeting agenda and list of participants.

The meeting began with a review of recent changes in the antiretroviral therapy landscape in low- and middle-income countries from the WHO perspective. This includes the addition of dolutegravir (DTG)-based regimens as a preferred option for first-line therapy and observations regarding the safety of DTG for women of childbearing potential. These developments, in the context of increasing rates of pretreatment HIV drug resistance in many countries and especially among women, raise important issues that could affect WHO treatment guidelines. The five pillars of the Global Action Plan and the HIVResNet governance structure were also reviewed. This introduction was then followed by 10 thematically divided sessions of public health relevance.

EXECUTIVE SUMMARY

WHO convened the HIVResNet meeting in Johannesburg, South Africa, on 21 October 2018. The meeting was attended by 60 HIV drug resistance experts from all over the world. The most important points discussed and conclusions from each session are summarized below.

Session 1: Sanger versus next-generation sequencing: optimal reporting thresholds for comparability and reproducibility

- ✓ Maximum identity to the Sanger consensus sequence was achieved at a threshold of 20%.

Session 2: Could a more affordable genotyping test affect its use in clinical practice in low- and middle-income countries and how?

- ✓ At least nine African countries among those who responded to the survey reported having national policies recommending the use of HIV drug resistance genotyping for people for whom second-line antiretroviral therapy regimens are failing. In some cases, reagent costs for sequencing of protease (PR), reverse-transcriptase (RT) and integrase (IN) may be as low as US\$ 30 to US\$ 50. HIV drug resistance testing was considered cost-effective for this group of people, since the cost of third-line antiretroviral therapy is high and levels of resistance to protease inhibitors (PIs) among second-line failures is relatively low (typically <40%).

Session 3: What is the risk of HIV drug resistance emerging among pre-exposure prophylaxis (PrEP) users in low- and middle-income countries?

- ✓ Data from clinical trials show that resistance is infrequent (3%) from oral tenofovir (TDF) + emtricitabine (FTC) PrEP if HIV-1 infection is not present when PrEP is started but is more common (41%) if TDF + FTC PrEP is started during undiagnosed acute HIV-1 infection. More data from programmes scaling up PrEP are needed.

Session 4: Dolutegravir roll-out in the context of non-nucleoside reverse-transcriptase inhibitor (NNRTI) pretreatment HIV drug resistance

- ✓ DTG roll-out has been slowed because of safety concerns for women of childbearing potential. This has complicated the recommended selection of optimal first-line antiretroviral therapy regimens in populations with elevated prevalence of pretreatment HIV drug resistance. In countries with NNRTI pretreatment HIV drug resistance prevalence >10%, WHO guidelines recommend urgently considering non-NNRTI (DTG or ritonavir-boosted atazanavir, ATV/r)-based first-line regimens for everyone initiating antiretroviral therapy.
- ✓ Informal poll among participants: in a country with NNRTI pretreatment HIV drug resistance >10%, no consistent access to contraception, for women starting first-line therapy: what regimen should be recommended?

• Tenofovir, lamivudine/emtricitabine, dolutegravir (TLD): 60%

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24372

